Nexalin Technology, Inc.

Nexalin Technology is a medical device company that develops non-invasive cranial electrotherapy stimulation (CES) devices to treat mental health and neurological disorders without pharmaceuticals. The company manufactures and licenses proprietary waveform technology products across three generations: legacy Gen-1 devices that now generate recurring revenue through licensing and accessories; Gen-2 SYNC, a clinical device targeting anxiety, insomnia, and dementia currently in regulatory review; and Gen-3 HALO, a consumer headset for home use integrated with telehealth platforms. Nexalin generates revenue through licensing fees and accessory sales in the U.S., international regulatory approvals and sales partnerships in China, Brazil, and other markets, and plans to launch a virtual clinic model combining remote psychiatric diagnosis with home-based device prescription and cloud-based physician monitoring, while pursuing insurance reimbursement coverage.